利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.018 秒)

    Methods for treating inflammatory conditions
    2.
    发明授权
    Methods for treating inflammatory conditions 失效
    治疗炎症的方法

    公开(公告)号：US06190691B1

    公开(公告)日：2001-02-20

    申请号：US09097440

    申请日：1998-06-15

    申请人： Vivien H. W. Mak

    发明人： Vivien H. W. Mak

    IPC分类号： A61F1300

    CPC分类号： A61K31/585 ,  A61K31/277 ,  A61K31/341 ,  A61K31/4174 ,  A61K31/4422 ,  A61K31/451 ,  A61K31/522 ,  A61K31/554 ,  Y10S514/859 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/886 ,  Y10S514/887

    摘要： The present invention provides a number of screening methods for evaluating compounds capable of suppressing cytokine production either in vitro or in vivo. The methods generally involve stimulating the production of a cytokine in a cell, exposing a portion of the cells to a putative cytokine modulating agent and determining subsequent levels of cytokine production in the cells. Additionally, the present invention provides certain compounds identified by this method.

    摘要翻译： 本发明提供了用于评估能够在体外或体内抑制细胞因子产生的化合物的多种筛选方法。 所述方法通常涉及刺激细胞中细胞因子的产生，将一部分细胞暴露于推定的细胞因子调节剂并确定细胞中细胞因子产生的后续水平。 此外，本发明提供了通过该方法鉴定的某些化合物。

    Diffusion test apparatus and method
    4.
    发明授权
    Diffusion test apparatus and method 失效
    扩散试验装置及方法

    公开(公告)号：US5490415A

    公开(公告)日：1996-02-13

    申请号：US227964

    申请日：1994-04-15

    申请人： Vivien H. W. Mak ,  Michael L. Francoeur

    发明人： Vivien H. W. Mak ,  Michael L. Francoeur

    IPC分类号： G01N13/00 ,  G01N13/04 ,  G01N33/15 ,  G01N35/00

    CPC分类号： G01N13/00 ,  G01N13/04 ,  G01N2035/00198 ,  G01N33/15

    摘要： A diffusion test apparatus (2), used to test diffusion of a drug within a vehicle through a test membrane (8), includes a receiver assembly (6) and a donor assembly (4) secured to one another. The receiver assembly includes a number of open-top receiver receptacles (26) arranged in a chosen pattern along its face (12). Similarly, the donor assembly includes a number of open-top donor receptacles (38) arranged along its face (10) in a mirror image of the chosen pattern. The test membrane is captured between the receiver and donor faces. The drug diffuses through the test membrane and into the receiver liquid (53) during an incubation period (62). Samples (66) of the receiver liquid are preferably automatically transferred to a conventional microtiter plate (70) using a programmed liquid transfer system for assay by a scintillation counter (76).

    摘要翻译： 用于通过测试膜（8）测试车辆内的药物扩散的扩散测试装置（2）包括彼此固定的接收器组件（6）和供体组件（4）。 接收器组件包括沿着其表面（12）以选定的图案布置的多个敞开式接收器插座（26）。 类似地，施主组件包括沿所选择的图案的镜像沿着其面（10）布置的多个开顶施主插座（38）。 测试膜被捕获在接收器和供体面之间。 在潜伏期（62）期间，药物通过测试膜扩散入接收液体（53）。 接收液体的样品（66）优选使用编程的液体转移系统自动转移到常规微量滴定板（70），以便通过闪烁计数器（76）进行测定。

    Compounds and methods for the treatment of urogenital disorders
    5.
    发明授权
    Compounds and methods for the treatment of urogenital disorders 失效

    公开(公告)号：US06987129B2

    公开(公告)日：2006-01-17

    申请号：US10094409

    申请日：2002-03-06

    申请人： Vivien H. W. Mak ,  Stephen Grayson

    发明人： Vivien H. W. Mak ,  Stephen Grayson

    IPC分类号： A61K31/21 ,  A61K31/195 ,  A61K31/155 ,  A61K31/535

    CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/5513 ,  A61K31/554 ,  A61K31/56 ,  A61K38/446 ,  A61K38/4886 ,  A61K2300/00

    摘要： The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates and cGMP-dependent protein kinase activators (e.g., cGMP mimetics).